Asia has become the world\u2019s fastest growing healthcare market, projected to reach US$5 trillion by 2030.<\/p>\n
The boom is underpinned by the region\u2019s aging populations, complemented by expansion of the middle-class.<\/p>\n
As healthcare demand rises, healthcare providers, health-tech innovators and health-related infrastructure across Asia are poised to benefit.<\/p>\n
Here are three resilient companies that are tapping into Asia\u2019s healthcare boom.<\/p>\n
Raffles Medical Group (SGX: BSL)<\/p>\n
Raffles Medical Group (RMG) is a Singapore-based integrated healthcare provider operating hospitals and clinic services across Asia.<\/p>\n
In the first half of 2025 ending 30 June 2025 (1H 2025), the company reported a revenue growth of 3.5% year-on-year (YoY) to S$378.4 million.<\/p>\n
A key driver is its Raffles Health Insurance segment, where revenue climbed by 10% YoY to S$94.9 million, and Hospital Services which experienced a gain of 3.8% YoY to S$174 million.\u00a0<\/p>\n
Further down the line, the company saw a rise in profits of 5% YoY to S$32.5 million.
This growth is primarily driven by its Hospital Services segment with segment profits increasing by 24.3% YoY to S$17.7 million.<\/p>\n
RMG is also steadily building its reputation as a premium healthcare provider in China.\u00a0<\/p>\n
For 1H 2025, RMG\u2019s Greater China division saw a rise of 2% YoY based on constant currency.\u00a0<\/p>\n
The firm also plans to further expand in this market with strategic partnerships with Shanghai Renji Hospital and Chongqing\u2019s First Affiliated Hospital.<\/p>\n
Currently, RMG sports a trailing price-to-earnings (PE) ratio of over 29 which is greater than the Straits Times Index (SGX: STI) P\/E ratio around 14.25 times.<\/p>\n
The premium valuation suggests that investors are optimistic on RMG\u2019s future growth, likely due to its strong regional exposure and the tailwinds of the medical tourism trend \u2014 a market set to reach nearly US$705 billion by 2033.<\/p>\n
Abbott Laboratories (NYSE: ABTT)<\/p>\n
Abbott Laboratories is a global healthcare company with a diverse set of products, ranging from diagnostics, medical devices, nutrition and branded generic pharmaceuticals.<\/p>\n
For the third quarter of 2025 ending on 30 September 2025 (3Q 2025), the firm saw a 6.9% YoY gain in revenue to US$11.4 billion.<\/p>\n
Abbott also managed to maintain a net profit of US$1.6 billion albeit with a minor decrease of 0.1% YoY.<\/p>\n
One of the main contributors for its financial performance comes from the diabetes care medical devices segment.<\/p>\n
This segment showed a sales growth of 19.3% YoY to US$2 billion.<\/p>\n
This increase can be attributed to the success of its FreeStyle Libre continuous glucose monitors (CGM).<\/p>\n
This popular device is known for its real-time tracking, data sharing ecosystem, non-invasiveness, and affordability.<\/p>\n
Furthermore, Abbott launched new products in India enabling it to capture the growing demand for medical devices in Asia.<\/p>\n
On 21 August 2025, Abbott announced its launch of the FreeStyle Libre 2 Plus in India.
This is an upgrade of their best selling CGM with improved features such as greater accuracy, real-time glucose alarms, and suitability for younger users.<\/p>\n
On 6 October 2025, the company announced the launch of AVEIR\u2122 DR in India.<\/p>\n
The AVEIR\u2122 DR is the world\u2019s first dual-chamber leadless pacemaker.<\/p>\n
This innovation reduces implantation complications, patient comfort due to its compact structure, and dual-pacing capabilities enabled by Abbott\u2019s proprietary technology.<\/p>\n
Moreover, Abbott shows healthy fundamentals with a dividend<\/a> yield of 1.9% and a payout ratio of around 29%.<\/p>\n The stock has a decent valuation as its PE ratio is 16.<\/p>\n ParkwayLife REIT (SGX: C2PU)<\/p>\n ParkwayLife REIT or (PLife) is a Singaporean healthcare real estate investment trust<\/a> (REIT) that owns three hospitals in Singapore, and multiple nursing homes in Japan and France.<\/p>\n For 9M 2025, PLife experienced an 8.2% YoY increase in gross revenue to S$117.3 million.<\/p>\n The REIT also delivered an 8.1% YoY gain in net property income to S$110.7 million.<\/p>\n That said, PLife only reported an increase of 2.3% YoY for its distribution per unit<\/a> (DPU) to S$0.1156.<\/p>\n The growth is attributed to Singapore hospitals with step-up lease agreements and acquisitions in 2024.<\/p>\n These acquisitions include the nursing homes in France and Japan.<\/p>\n For PLife\u2019s Singapore operations, the assets come with long master leases on hospitals which were recently renewed.<\/p>\n The renewal term is 20.4 years from 22 August 2022 to 31 December 2042, hence a low lease-expiry risk.<\/p>\n In addition, the company has a healthy gearing of 35.8%, well below the regulatory gearing limit of 50%.<\/p>\n This gearing value points to a strong balance sheet and a higher capacity to take on more debt for projects and refinancing.<\/p>\n Get Smart: Invest in Asia\u2019s Healthcare future<\/p>\n The Asia healthcare boom is not a cyclical upswing but a long-term market shift.<\/p>\n The increase in purchasing power in Asia and its growing ageing population results in the increase in demand for healthcare products and services.<\/p>\n A report by the Organisation for Economic Co-operation and Development (OECD), stated that the per capita health expenditure of<\/p>\n nearly all Asia-Pacific countries has risen faster than GDP in recent years.<\/p>\n The three stocks tap into different aspects of the value chain in Asia\u2019s expanding healthcare ecosystem.<\/p>\n For investors, this trend translates to the opportunity to position early in resilient stocks with structural upside.<\/p>\n If dividends are part of your long-term plan, this is one session you won\u2019t want to miss. We\u2019ll break down the market forces driving 2026\u2019s dividend potential and highlight areas worth watching. Sign up now<\/a> for your free slot in our webinar, The Big Singapore Stock Market Rebound (2026\u2019s Dividend Opportunity).<\/p>\n If you want to retire with a constant stream of dividends, these 5 stocks might be all you need. We\u2019ve found 5 SG stocks that have kept paying (and growing) through inflation, rate hikes, and recessions. See what they are with our latest free report for SGX dividend investors. Click here<\/a> to get instant access.<\/p>\n Follow us on Facebook<\/a>, Instagram<\/a> and Telegram<\/a> for the latest investing news and analyses!<\/p>\n Disclosure: Gabriel does not own shares in any of the companies mentioned.<\/p>\n \t